BioSpace News Archive

CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the fourth quarter and fiscal year ended December 31, 2020. (NASDAQ: IBRX) (“ImmunityBio”) an

Seagen will supply Pieris with TUKYS to evaluate the drug in combination with cinrebafusp alfa (PRS-343) in gastric cancer Pieris co-development option for one program from existing multi-target collaboration amended to US co-promotion option with increased royalties if exercised

Cortexyme to Present at the Stifel 3 rd Annual CNS Day on April 1, 2021

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2020.

Cybin Inc. announces its placement in an editorial published by NetworkNewsWire, one of 50+ trusted brands within the InvestorBrandNetwork, a multifaceted financial news and publishing company for private and public entities.

Align Technology, Inc., makers of the Invisalign® clear aligner system, announced a partnership with U.S. Ski & Snowboard, making the Invisalign brand the Official Smile of U.S. Ski & Snowboard, the Olympic national governing body of ski and snowboard sports in the United States.

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a pooled analysis of Phase 3 data on the use of DSUVIA for acute pain management

New recommendations to advance racial equity, ways to mitigate the impacts of the COVID-19 pandemic on cancer care, and ongoing strategies for preventing and controlling HPV-associated cancers led the conversation at the National Comprehensive Cancer Network® (NCCN®) 2021 Virtual Annual Conference March 18-20.

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol ® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1) 100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement in at least 2 domains of the 17-domain NPC Severity Scale

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, Inc., a subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151)